Phosphagenics appoints pharma veteran

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.

Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.

Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.

Ashton also served as CEO for SkyePharma PLC.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

The important role of software engineering in industry

Biome Australia brings probiotic manufacturing to Australia

Propel-AIR applications closing this week

AMS announces 2026 Beamex User Group meeting

A high-speed, real-time optical data connection for industrial applications

Airport receives sustainability certification

Counting down to Singapore International Water Week 2026

AMS announces 2026 Beamex User Group meeting

Businesses use AI to manage sustainability reporting

Victorian wind farm project to power 1.2 million homes

Six key pillars of frailty prevention and management

Protecting the people who protect us: PPE continuity during demand surge

WA steps in to ensure 'continuity' of operations at Mount Private Hospital

What healthcare boards need from risk leaders

Additional $22.9m in research grants for nation's biggest killer